These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23601167)

  • 21. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.
    Skalitzky DJ; Marakovits JT; Maegley KA; Ekker A; Yu XH; Hostomsky Z; Webber SE; Eastman BW; Almassy R; Li J; Curtin NJ; Newell DR; Calvert AH; Griffin RJ; Golding BT
    J Med Chem; 2003 Jan; 46(2):210-3. PubMed ID: 12519059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.
    Wang Z; Qian H; Yiu SM; Sun J; Zhu G
    J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling.
    Ishida J; Yamamoto H; Kido Y; Kamijo K; Murano K; Miyake H; Ohkubo M; Kinoshita T; Warizaya M; Iwashita A; Mihara K; Matsuoka N; Hattori K
    Bioorg Med Chem; 2006 Mar; 14(5):1378-90. PubMed ID: 16288880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PARP inhibitors for anticancer therapy.
    Curtin N
    Biochem Soc Trans; 2014 Feb; 42(1):82-8. PubMed ID: 24450632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
    Liu X; Shi Y; Maag DX; Palma JP; Patterson MJ; Ellis PA; Surber BW; Ready DB; Soni NB; Ladror US; Xu AJ; Iyer R; Harlan JE; Solomon LR; Donawho CK; Penning TD; Johnson EF; Shoemaker AR
    Clin Cancer Res; 2012 Jan; 18(2):510-23. PubMed ID: 22128301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.
    Kumar C; Rani N; Velan Lakshmi PT; Arunachalam A
    Future Med Chem; 2017 Jan; 9(1):37-60. PubMed ID: 27995810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poly (ADP-ribose) polymerase inhibitors in cancer treatment.
    Mason KA; Raju U; Buchholz TA; Wang L; Milas ZL; Milas L
    Am J Clin Oncol; 2014 Feb; 37(1):90-100. PubMed ID: 22495455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888.
    Karlberg T; Hammarström M; Schütz P; Svensson L; Schüler H
    Biochemistry; 2010 Feb; 49(6):1056-8. PubMed ID: 20092359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo.
    Thomas C; Ji Y; Lodhi N; Kotova E; Pinnola AD; Golovine K; Makhov P; Pechenkina K; Kolenko V; Tulin AV
    EBioMedicine; 2016 Nov; 13():90-98. PubMed ID: 27727003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poly(ADP-ribose)polymerase inhibition - where now?
    Woon EC; Threadgill MD
    Curr Med Chem; 2005; 12(20):2373-92. PubMed ID: 16181138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The antimitotic potential of PARP inhibitors, an unexplored therapeutic alternative.
    Iglesias P; Costoya JA
    Curr Top Med Chem; 2014; 14(20):2346-65. PubMed ID: 25434352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive biomarkers for cancer therapy with PARP inhibitors.
    Michels J; Vitale I; Saparbaev M; Castedo M; Kroemer G
    Oncogene; 2014 Jul; 33(30):3894-907. PubMed ID: 24037533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.
    Drew Y; Plummer R
    Drug Resist Updat; 2009 Dec; 12(6):153-6. PubMed ID: 19939726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
    Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
    Horvath EM; Szabó C
    Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PARP inhibition: PARP1 and beyond.
    Rouleau M; Patel A; Hendzel MJ; Kaufmann SH; Poirier GG
    Nat Rev Cancer; 2010 Apr; 10(4):293-301. PubMed ID: 20200537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Towards small molecule inhibitors of mono-ADP-ribosyltransferases.
    Ekblad T; Lindgren AE; Andersson CD; Caraballo R; Thorsell AG; Karlberg T; Spjut S; Linusson A; Schüler H; Elofsson M
    Eur J Med Chem; 2015 May; 95():546-51. PubMed ID: 25847771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies Employed for the Development of PARP Inhibitors.
    Canan S; Maegley K; Curtin NJ
    Methods Mol Biol; 2017; 1608():271-297. PubMed ID: 28695516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.